AbD Serotec Selected as Preferred Supplier for Custom Monoclonal Antibody Generation by Research Councils UK for UK Research
MorphoSys AG announced that its research and diagnostic antibodies unit AbD Serotec has signed a two year contract for the supply of custom monoclonal antibodies with Research Councils UK Shared services Centre Limited (RCUK SSC Ltd). RCUK SSC Ltd has been set up by the seven Research Councils of the UK (RCUK) to provide centralized services to the Research Councils and their institutes in various areas including procurement.
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
![Topic world Antibodies](http://static.chemie.de//media/images/focuspage/022d2694-7e7f-411e-9219-c2cf6ea89d36.png)
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous